Supplementary Figure S14 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Q: What type of study is this?

This is a RCT study (also classified as: Phase 2).

Chang Gon Kim; Min Hee Hong; Dahee Kim; Brian Hyohyoung Lee; Hyunwook Kim; Chan‐Young Ock; Geoffrey Kelly; Yoon Ji Bang; Gamin Kim; Jung Eun Lee; Chaeyeon Kim; Se‐Heon Kim; Hyun Jun Hong; Young Min Park; Nam Suk Sim; Heejung Park; Jin Woo Park; Chang Geol Lee; Kyung Hwan Kim; Goeun Park; Inkyung Jung; Dawoon Han; Jong Hoon Kim; Junha Cha; Insuk Lee; Mingu Kang; Heon Song; Chiyoon Oum; Seulki Kim; Sukjun Kim; Yoojoo Lim; Seunghee Kim‐Schulze; Miriam Mérad; Sun Och Yoon; Hyun Je Kim; Yoon Woo Koh; Hye Ryun Kim

doi:10.1158/1078-0432.29996697

Key Points

The trial finds that treatment with durvalumab alone or combined with tremelimumab affects CD8+ T cells in head and neck cancer.
High-dimensional profiling reveals distinct immune responses, with CD8+ T cell involvement being significant for treatment outcomes.
Conducted as a randomized clinical trial, phase II, which enables further exploration of immunotherapy in head and neck cancer.
These findings may support combinations of therapies as promising approaches for improving patient outcomes.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Open-label randomized clinical trial evaluates preoperative durvalumab alone or with tremelimumab in head and neck cancer, indicating potential immune response benefits.

Abstract

High-dimensional profiling of CD8+ T cells.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2025) studied this question.

synapsesocial.com/papers/68bb3a352b87ece8dc954d37 https://doi.org/10.1158/1078-0432.29996697

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S14 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S14 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers